Drugstore.com leadership
This article was originally published in The Tan Sheet
Executive Summary
Online retailer appoints Dawn Lepore as CEO, effective Oct. 11. Lepore currently is VP-technology, operations and administration at Charles Schwab, a member of Schwab's executive committee and a trustee of SchwabFunds; she will relinquish all of her Schwab positions when she joins Drugstore.com. Drugstore.com board member Melinda Gates says Lepore "brings a great deal of respect and depth from the e-commerce industry as both a leader and an innovator," having designed Schwab's "entire technology platform" and played a "key role" in that firm's online brokerage business. Lepore replaces interim CEO and current CFO Robert Barton, who took over after Kal Raman stepped down in June (1"The Tan Sheet" June 14, 2004, In Brief)...
You may also be interested in...
Drugstore.com
Online retailer's net sales increase 41% to $84.3 mil. with a net loss of $6.3 mil. in the firm's third quarter, drugstore.com reports Oct. 26. Over-the-counter segment revenues rose 37% to $35.2 mil. due in part to a wider array of nutritional products. CEO Dawn Lepore says the firm has made "encouraging progress in a number of key areas despite a critical management transition and a seasonally challenging period." Lepore took over as CEO in September (1"The Tan Sheet" Sept. 27, 2004, In Brief)...
Drugstore.com CEO resigns
Online retailer's President & CEO Kal Raman steps down to "pursue other opportunities," firm announces June 11. CFO Robert Barton will serve as interim CEO as the firm seeks a successor. During Raman's tenure, the company's annual revenues increased from $145 mil. in 2001 to $246 mil. in 2003; the firm achieved EBITDA profitability in the fourth quarter of 2003. Drugstore.com expects revenues for the second quarter to increase 50% to $85 mil. - $89 mil. with an EBITDA loss of $1.1 mil. to $1.8 mil. due to slow ramp-up of the Vision Direct business...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.